HST Medical, a renowned Singaporean health supplement provider, has been acquired by Kowa Pharmaceutical Asia, a subsidiary of Japan’s Kowa Company, effective 29 May 2026. This strategic move is set to enhance HST Medical’s global reach, leveraging Kowa’s established networks and expertise.
The acquisition allows HST Medical to operate as a wholly-owned subsidiary, maintaining its leadership and brand identity. The company, known for its Rheuma-Salve® pain relief balm, will now have access to Kowa’s global export networks, facilitating the distribution of its products across ASEAN and other international markets. Additionally, Kowa will support HST Medical in modernising its product line-up to cater to a broader audience.
Ellis Tan will continue as General Manager, whilst co-founder Simone Tan will take on the role of Director and Head of Business Development. President Nikhil Kapur expressed enthusiasm about the partnership, stating, “Joining forces with the Kowa Group represents a transformative chapter for HST Medical. By aligning HST Medical’s rich heritage of trust and consumer-focused innovation with Kowa’s global infrastructure and pharmaceutical expertise, we are not only scaling our reach but also ensuring that our science-backed wellness solutions can positively impact more lives internationally.”
Founded in 1930, HST Medical has a long-standing legacy in blending traditional remedies with modern science. The acquisition marks a significant step in its journey to becoming a global health and wellness brand, promising enhanced product offerings and expanded market presence.
